With the approval of monoclonal antibodies against ANGPTL3 by the Food and Drug Administration (FDA) and the European Medicines Agency as an add-on treatment for patients with HoFH, ANGPTL3 has gained widespread recognition as a therapeutic target. The gene discussed is ANGPTL3; the disease is homozygous familial hypercholesterolemia.